Treatment With Bulevirtide in HIV Infected patients With chronic Hepatitis Delta. ANRS HD EP01 BULEDELTA & Compassionate Cohort

• Published in: JHEP reports
• Main Authors: de Lédinghen, Victor, Fougerou-Leurent, Claire, Le Pabic, Estelle, Pol, Stanislas, Alfaiate, Dulce, Lacombe, Karine, Hilleret, Marie-Noëlle, Lascoux-Combe, Caroline, Minello, Anne, Billaud, Eric, Rosa, Isabelle, Gervais, Anne, Ratziu, Vlad, Ganne, Nathalie, Pageaux, Georges-Philippe, Leroy, Vincent, Loustaud-Ratti, Véronique, Mathurin, Philippe, Chas, Julie, Jezequel, Caroline, Métivier, Sophie, Dumortier, Jérôme, Arpurt, Jean-Pierre, Asselah, Tarik, Roche, Bruno, Le Gruyer, Antonia, Valantin, Marc-Antoine, Scholtès, Caroline, Gordien, Emmanuel, Tual, Christelle, Kortebi, Amel, Coulibaly, Fatoumata, Rosenthal, Eric, Subic-Levrero, Miroslava, Roulot, Dominique, Zoulim, Fabien, Bourlière, Marc, Marcellin, Fabienne, Gaudy-Graffin, Catherine, Guedj, Jeremie, Sizorn, Michelle, L’hénaff, Marianne, Landry, Elise, Levrero, Massimo, Mecheri, Manal, Petrov-Sanchez, Ventzislava, Renault, Alain, Serfaty, Lawrence, Raffi, François, Alric, Laurent, Miailhes, Patrick, Tran, Albert, Stern, Christiane, Causse, Xavier, Tripon, Simona, Riachi, Ghassan, Chazouillères, Olivier, Abergel, Armando, Gournay, Jérôme, Lagadic, Garance, Carrieri, Patrizia, Brichler, Ségolène, Siguier, Martin, Krause, Jessica, Foucher, Juliette, Ben Ali, Souad, Meszaros, Magdalena, Varaut, Anne, Canva, Valérie
• Format: Journal Article
• Language: English
• Published: Elsevier 01.03.2024
• Subjects: Life Sciences; Cirrhosis; HIV; HIV RNA; entry inhibitors; hepatitis D; HBV DNA; HDV-RNA; pegylated interferon; HDV; HBV
• ISSN: 2589-5559
• DOI: 10.1016/j.jhepr.2024.101057

Background and AimsIn France, Bulevirtide (BLV) was available in September 2019 through an early access program to treat patients with hepatitis Delta virus (HDV). The aim of this analysis was to evaluate the efficacy and safety of BLV in HIV patients with HDV coinfection.Patients and methodsPatients received BLV 2 mg +/- pegylated interferon (pegIFNα) according to the physician’s decision. The primary endpoint (per-protocol analysis) was the virological response rate at week 48, defined as the proportion of patients with undetectable serum HDV-RNA or HDV-RNA decline > 2 log10 IU/mL from baseline.ResultsCharacteristics of the 38 patients were as follow: 28 male, mean age 47.7 years, mean baseline HDV-RNA viral load 5.7 ± 1.2 log10 IU/ml. Median HIV viral load and mean CD4 count were 32 (30 - 65) cp/ml and 566 ± 307/mm3, respectively. Eight patients stopped treatment before week 48. At W48, 10 of 19 patients (52.6%) in the 2 mg BLV group, and 5 of 7 patients (71.4%) in the 2 mg BLV + pegIFNα group had reached virological response (no HDV-RNA available in 4 patients). At W48, 7/19 patients in the 2 mg BLV group, and 3/6 patients in the 2 mg BLV + pegIFNα group had combined response (virological response and normal ALT level).ConclusionAdults living with HIV coinfected with HDV can be treated by BLV with a virological response in more than 50% of patients. The combination of BLV and pegIFNα showed a strong virological response.